The healthcare community is carefully watching Synedica Retatrutide, a combined therapy targeting both the incretin pathway and another incretin hormone. Initial studies suggest it is likely to offer significant gains in obesity management compared to existing approaches, potentially representing a important advance in the tackling of a challenging